Thermo Fisher Scientific Inc. $TMO Shares Bought by Waters Parkerson & CO. LLC

Waters Parkerson & CO. LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% in the third quarter, HoldingsChannel.com reports. The fund owned 160,034 shares of the medical research company’s stock after purchasing an additional 924 shares during the quarter. Thermo Fisher Scientific accounts for approximately 3.8% of Waters Parkerson & CO. LLC’s portfolio, making the stock its 6th biggest holding. Waters Parkerson & CO. LLC’s holdings in Thermo Fisher Scientific were worth $77,620,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 0.9% in the second quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock valued at $13,700,154,000 after buying an additional 309,207 shares during the period. Norges Bank bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $2,264,615,000. Franklin Resources Inc. boosted its position in Thermo Fisher Scientific by 11.3% during the second quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock worth $1,985,759,000 after purchasing an additional 498,238 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 2.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock valued at $1,216,612,000 after purchasing an additional 74,971 shares during the last quarter. Finally, Flossbach Von Storch SE raised its position in shares of Thermo Fisher Scientific by 93.0% in the second quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after purchasing an additional 1,314,182 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on TMO shares. Stifel Nicolaus raised their price objective on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, January 7th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $625.47.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 7,250 shares of the stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $64,400,668.20. This trade represents a 5.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Lisa P. Britt sold 1,058 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the sale, the vice president owned 13,087 shares in the company, valued at approximately $7,698,558.62. The trade was a 7.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 149,271 shares of company stock valued at $86,507,282. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $619.16 on Friday. The stock has a fifty day simple moving average of $586.34 and a 200 day simple moving average of $523.82. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $629.87. The company has a market capitalization of $232.62 billion, a price-to-earnings ratio of 35.77, a PEG ratio of 4.11 and a beta of 0.91. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were issued a $0.43 dividend. The ex-dividend date was Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.